| 词条 | Thymopentin |
| 释义 |
| verifiedrevid = 470609802 | IUPAC_name = L-arginyl-L-lysyl-L-α-aspartyl-L-valyl-L-tyrosine | image = Thymopentin.png | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = | ATC_prefix = L03 | ATC_suffix = AX09 | PubChem = 451417 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 397640 | NIAID_ChemDB = 000127 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = O3Y80ZF13F | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D06117 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 156025 | C=30 | H=49 | N=9 | O=9 | molecular_weight = 679.76496 g/mol | smiles = O=C(N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)Cc1ccc(O)cc1)C(C)C)CC(=O)O)CCCCN)[C@@H](N)CCC/N=C(\)N | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C30H49N9O9/c1-16(2)24(28(46)38-22(29(47)48)14-17-8-10-18(40)11-9-17)39-27(45)21(15-23(41)42)37-26(44)20(7-3-4-12-31)36-25(43)19(32)6-5-13-35-30(33)34/h8-11,16,19-22,24,40H,3-7,12-15,31-32H2,1-2H3,(H,36,43)(H,37,44)(H,38,46)(H,39,45)(H,41,42)(H,47,48)(H4,33,34,35)/t19-,20-,21-,22-,24-/m0/s1 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = PSWFFKRAVBDQEG-YGQNSOCVSA-N | synonyms = (3S)-3-{{bracket|[(2S)-6-amino-2{bracket|[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino}}hexanoyl]amino}4-{{bracket|[(2S)-1{bracket|[(2S)-1-hydroxy-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino}3-methyl-1-oxobutan-2-yl]amino}}-4-oxobutanoic acid }}Thymopentin is an immunostimulant. As such, it has been used in several clinical studies in the early years of the AIDS pandemic (from 1983 to 1985). Thymopentin helped to improve immunological condition in several patients for a brief time under specific treatments.[1][2][3] It interacts with T cells.[4] It is a thymic polypeptide.[5] References1. ^{{cite journal |vauthors=Mascart-Lemone F, Huygen K, Clumeck N, Brenez D, Bolla K, Duchateau J |title=Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients |journal=Lancet |volume=322 |issue=8352 |pages=735–736 |year=1983 |pmid=6193382 |doi=10.1016/S0140-6736(83)92271-7 |url=http://www.lancet.com/journals/lancet/article/PIIS0140-6736(83)92271-7/fulltext}} {{Immunostimulants}}{{antineoplastic-drug-stub}}2. ^{{cite journal |vauthors=Clumeck N, Van de Perre P, Mascart-Lemone F, Cran S, Bolla K, Duchateau J |title=Preliminary results on clinical and immunological effects of thymopentin in AIDS |journal=Int J Clin Pharmacol Res |volume=4 |issue= 6|pages=459–463 |year=1984 |pmid=6398315 |url=http://europepmc.org/abstract/MED/6398315}} 3. ^{{cite journal |vauthors=Clumeck N, Cran S, Van de Perre P, Mascart-Lemone F, Duchateau J, Bolla K |title=Thymopentin treatment in AIDS and pre-AIDS patients |journal=Surv Immunol Res |volume=4 |issue=1 |pages=supp1 58–62 |year=1985 |pmid=3898293 |url=https://link.springer.com/article/10.1007%2FBF02919057 |doi=10.1007/BF02919057|doi-broken-date=2019-03-15 }} 4. ^{{cite journal |vauthors=Liu Z, Zheng X, Wang J, Wang E |editor1-last=Egli |editor1-first=Martin |title=Molecular analysis of thymopentin binding to HLA-DR molecules |journal=PLoS ONE |volume=2 |issue=12 |pages=e1348 |year=2007 |pmid=18159232 |pmc=2137936 |doi=10.1371/journal.pone.0001348 }} {{open access}} 5. ^{{cite journal |vauthors=Peng Y, Chen Z, Yu W, etal |title=Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells |journal=Cell Biology International |volume= 32|issue= 10|pages= 1265–71|date=July 2008 |pmid=18692582 |doi=10.1016/j.cellbi.2008.07.011 |url=http://linkinghub.elsevier.com/retrieve/pii/S1065-6995(08)00501-5}} 2 : Peptides|Immunostimulants |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。